×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VRAX – virax biolabs group limited - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VRAX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/4
04:50 pm
vrax
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement [Yahoo! Finance]
Medium
Report
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement [Yahoo! Finance]
12/4
04:05 pm
vrax
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
Low
Report
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
12/3
03:26 pm
vrax
Virax Biolabs Group Limited Announces $5 Million Private Placement [Yahoo! Finance]
High
Report
Virax Biolabs Group Limited Announces $5 Million Private Placement [Yahoo! Finance]
12/3
01:53 pm
vrax
Virax Biolabs Group Limited Announces $5 Million Private Placement
Medium
Report
Virax Biolabs Group Limited Announces $5 Million Private Placement
12/3
07:34 am
vrax
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
High
Report
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
11/3
08:29 am
vrax
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes
Medium
Report
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes
10/14
12:17 pm
vrax
Virax Biolabs Group (NASDAQ:VRAX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Virax Biolabs Group (NASDAQ:VRAX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/4
04:07 pm
vrax
Form 6-K Virax Biolabs Group Ltd For: Dec 04
Medium
Report
Form 6-K Virax Biolabs Group Ltd For: Dec 04
12/2
04:42 pm
vrax
Form 6-K Virax Biolabs Group Ltd For: Dec 02
High
Report
Form 6-K Virax Biolabs Group Ltd For: Dec 02
10/29
05:16 pm
vrax
Form SCHEDULE 13G/A Virax Biolabs Group Ltd Filed by: Foster James Alexander Cunliffe
Medium
Report
Form SCHEDULE 13G/A Virax Biolabs Group Ltd Filed by: Foster James Alexander Cunliffe
10/29
05:16 pm
vrax
Form SCHEDULE 13G/A Virax Biolabs Group Ltd Filed by: Foster James Alexander Cunliffe
Medium
Report
Form SCHEDULE 13G/A Virax Biolabs Group Ltd Filed by: Foster James Alexander Cunliffe
10/29
05:11 pm
vrax
Form SCHEDULE 13G/A Virax Biolabs Group Ltd Filed by: Foster James Alexander Cunliffe
High
Report
Form SCHEDULE 13G/A Virax Biolabs Group Ltd Filed by: Foster James Alexander Cunliffe
10/29
05:10 pm
vrax
Form SCHEDULE 13G Virax Biolabs Group Ltd Filed by: Foster James Alexander Cunliffe
Low
Report
Form SCHEDULE 13G Virax Biolabs Group Ltd Filed by: Foster James Alexander Cunliffe
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: